ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2162

Frequent Discussion of Insomnia and Weight Gain with Glucocorticoid Therapy: An Analysis of Twitter Posts

Rikesh Patel1, Nabarun Dasgupta2, Maksim Belousov3, Meghna Jani4, Carly Winokur2, Goran Nenadic3 and William G Dixon1,5, 1Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 2Epidemico Inc., Boston, MA, 3School of Computer Sciences, The University of Manchester, Manchester, United Kingdom, 4Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 5Manchester Academic Health Sciences Centre, Health e-Research Centre, Farr Institute for Health Informatics Research, The University of Manchester, Manchester, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: drug safety, prednisolone, prednisone, social media and steroids, Twitter

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Epidemiology and Public Health - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Glucocorticoid (GC) therapy is used widely in patients with inflammatory diseases. However their effectiveness is offset by a range of potential harms. Clinicians and patients have differing views on the importance of certain side effects with GC therapy, which can lead to misunderstanding and a breakdown in doctor-patient relationships. People now readily share their thoughts and experiences of health related matters on social media such as Twitter, including information about medications and their side effects. There are now vast amounts of information within this domain that could return useful knowledge about patient reported adverse events (AEs) with their medications. The aim of this study was to detect and quantify GC-related AEs using a computerised system for automated suspected adverse drug reaction (ADR) detection from narrative text in Twitter.

Methods: All Tweets mentioning prednisolone or prednisone between 1st October 2012 and 30th June 2015 were acquired and anonymised before being processed through automated natural language processing software which mapped possible symptoms (e.g. can’t sleep) to preferred terms (PTs) in the Medical Dictionary for Regulatory Activities (MedDRA®) dictionary (e.g. insomnia). Tweets were automatically categorised using a Bayesian probabilistic model based on their likelihood of containing text relating to a GC related adverse drug reaction (ADR). Tweets with high probability of containing an ADR, defined as proto-AE tweets, were further analysed to determine which AE symptoms appeared most commonly.

Results: There were 81,524 distinct tweets mentioning prednisolone or prednisone between the specified dates. 20,206 were identified as proto-AEs i.e. had a high probability of representing an ADR. Within proto-AE tweets, 26,894 unique PTs were captured. The 5 most commonly reported PTs in proto-AE tweets were ‘insomnia’ (8.6%), ‘weight increased’ (8.2%), ‘non-specific reaction’ (7.8%), ‘increased appetite’ (7.5%) and ‘malaise’ (4.4%) (Figure 1). The top 5 and 25 PTs accounted for 25.0% and 74.6% of all AE PTs respectively.

Conclusion: Insomnia and weight gain were the most frequently reported GC-related AEs posted on Twitter. There remains a disconnect between the frequency of these patient reported AEs and our collective knowledge about these events. Pharmacovigilance in Twitter has the potential to be a valuable, supplementary source of data for determining which drug side effects patients most commonly find troublesome

Figure 1: Glucocorticoid related AE PTs reported in Twitter

 


Disclosure: R. Patel, None; N. Dasgupta, Epidemico Inc., 3; M. Belousov, None; M. Jani, None; C. Winokur, Epidemico Inc., 3; G. Nenadic, None; W. G. Dixon, None.

To cite this abstract in AMA style:

Patel R, Dasgupta N, Belousov M, Jani M, Winokur C, Nenadic G, Dixon WG. Frequent Discussion of Insomnia and Weight Gain with Glucocorticoid Therapy: An Analysis of Twitter Posts [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/frequent-discussion-of-insomnia-and-weight-gain-with-glucocorticoid-therapy-an-analysis-of-twitter-posts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequent-discussion-of-insomnia-and-weight-gain-with-glucocorticoid-therapy-an-analysis-of-twitter-posts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology